Trials / Completed
CompletedNCT00950690
Efficacy and Tolerability of Xalatan in Patients
Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,289 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
Detailed description
* Efficacy data not collected or analyzed * Safety and tolerability of Xalatan assessed NA
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalatan 0.005% eye drops | ophthalmic solution dosed once daily for 3 months |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2009-08-03
- Last updated
- 2021-02-25
- Results posted
- 2009-08-03
Locations
3 sites across 3 countries: Egypt, Saudi Arabia, United Arab Emirates
Source: ClinicalTrials.gov record NCT00950690. Inclusion in this directory is not an endorsement.